Neuropore Therapies, Inc. announced today that it has licensed two mechanistically distinct classes of potent, selective and brain penetrating modulators of mTOR–regulated autophagy to Global Cancer Technology.
Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.
